Targeting integrin/CD49D/VLA-4 with natalizumab can inhibit adhesion of malignant B cells and sensitize them to chemoimmunotherapy

• Authors: MRÁZ Marek; ZENT C.; CHURCH A.; JELINEK D.; POSPÍŠILOVÁ Šárka; ANSELL S.; NOVAK A.; WITZIG T.; NOWAKOWSKI G.
• Year of publication: 2010
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine

Related projects

• Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies